Giovanni Dothel

Giovanni Dothel

Auto-generated profile, based on publicly available information

Giovanni Dothel

Department of Medical and Surgical Sciences (DIMEC) University of Bologna Bologna Italy

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
GDGiovanni Dothel
Giovanni Dothel
MBMaria Raffaella Barbaro
Maria Raffaella Barbaro
HBHélène Boudin
Hélène Boudin
VVValentina Vasina
Valentina Vasina
CCCesare Cremon
Cesare Cremon
GBGiovanni Barbara
Giovanni Barbara

3 May 2011 in Current Gastroenterology Reports
Verified
Journal Article
Closed access
PDF file
GBGiovanni Barbara
Giovanni Barbara
CCCesare Cremon
Cesare Cremon
Roberto De GiorgioRoberto De Giorgio
Roberto De Giorgio
GDGiovanni Dothel
Giovanni Dothel
LZLisa Zecchi
Lisa Zecchi
RCRoberto Corinaldesi
Roberto Corinaldesi

2 September 2012 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
BBB. Balestra
B. Balestra
RVR. Vicini
R. Vicini
CCC. Cremon
C. Cremon
LZL. Zecchi
L. Zecchi
GDG. Dothel
G. Dothel
GBGiovanni Barbara
Giovanni Barbara

1 July 2013 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
GDGiovanni Dothel
Giovanni Dothel
VVValentina Vasina
Valentina Vasina
GBGiovanni Barbara
Giovanni Barbara
Fabrizio De PontiFabrizio De Ponti
Fabrizio De Ponti

1 January 2016 in World Journal of Gastroenterology
Verified
Journal Article
Open access
GDGiovanni Dothel
Giovanni Dothel
EREmanuel Raschi
Emanuel Raschi
RRrimondini roberto
rimondini roberto
Fabrizio De PontiFabrizio De Ponti
Fabrizio De Ponti
The past decade has witnessed an outstanding scientific production focused towards the possible clinical applications of mesenchymal stromal cells (MSCs) in autoimmune and chronic inflammatory diseases. This raised the need of novel standards to adequately address quality, efficacy and safety issues of this advanced therapy. The development of a streamlined regulation is currently hampered by the complexity of analyzing dynamic biological entities rather than chemicals. Although numerous pieces of evidence show efficacy in reducing intestinal inflammation, some inconsistencies between the mechanisms of action of rodent vs human MSCs suggest caution before assigning translational value to preclinical studies. Preliminary evidence from clinical trials showed efficacy of MSCs in the treatment of fistulizing Crohn’s disease (CD), and preparations of heterologous MSCs for CD treatment are currently tested in ongoing clinical trials. However, safety issues, especially in long-term treatment, still require solid clinical data. In this regard, standardized guidelines for appropriate dosing and methods of infusion could enhance the likelihood to predict more accurately the number of responders and the duration of remission periods. In addition, elucidating MSC mechanisms of action could lead to novel and more reliable formulations such as those derived from the MSCs themselves (e.g., supernatants).

4 January 2019 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
MMMartina Masotti
Martina Masotti
CDCecilia Delprete
Cecilia Delprete
GDGiovanni Dothel
Giovanni Dothel
V. DonadioV. Donadio
V. Donadio
RRrimondini roberto
rimondini roberto
MCMarco Caprini
Marco Caprini